Novartis today announced an update on the Phase III BELINDA study investigating Kymriah (tisagenlecleucel) in aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment. The BELINDA study did not meet its primary endpoint of event-free survival compared to treatment with the standard-of-care (SOC). SOC was salvage chemotherapy followed in responding patients by high-dose chemotherapy and stem cell transplant. The safety profile was consistent with the established safety profile of Kymriah.
- Read more about Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/novartis-provides-update-on-belinda-study-investigating-kymriah-as-second-line-treatment-in-aggressive-b-cell-non-hodgkin-lymphoma
No comments:
Post a Comment